News & Updates

Show Multimedia Only

Does adjuvant aspirin have a protective effect in resected PIK3CA-mutant colon cancer?

28 Aug 2025 by

Adjuvant aspirin is associated with clinically relevant disease-free survival (DFS) and time to disease recurrence (TTR) improvements, according to a phase III randomized, placebo-controlled trial.

Does adjuvant aspirin have a protective effect in resected PIK3CA-mutant colon cancer?

28 Aug 2025

Treatment further worsens physical function in NSCLC

26 Aug 2025

Patients with non-small cell lung cancer (NSCLC) already have poorer physical health and quality of life compared with healthy individuals. Treatment for this type of cancer makes these issues even worse, with patients becoming less physically active, according to a study.

Treatment further worsens physical function in NSCLC

26 Aug 2025

Dalpiciclib-pyrotinib-endocrine therapy passes trial for breast cancer

25 Aug 2025 by

Treatment with dalpiciclib combined with pyrotinib and endocrine therapy exhibits antitumour activity with no new safety signals in estrogen receptor (ER)-positive HER2-positive advanced breast cancer, as shown by the results of a phase II trial.

Dalpiciclib-pyrotinib-endocrine therapy passes trial for breast cancer

25 Aug 2025

Cancer history does not factor in COVID-19, related outcomes among older women

24 Aug 2025

A history of cancer in older women appears to have no negative impact on the risks of COVID-19 and its outcomes, as reported in a study.

Cancer history does not factor in COVID-19, related outcomes among older women

24 Aug 2025

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025 by

A lung nodule surveillance programme at Queen Mary Hospital (QMH) facilitates diagnosis of early-stage lung cancer. Data from the programme’s first year of implementation showed a higher proportion of early-stage lung cancer diagnoses compared with the Hong Kong Cancer Registry’s (HKCR) annual report.

Lung nodule surveillance programme helps detect early-stage lung cancer

22 Aug 2025

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025 by

A 65-year-old male with good past health presented in June 2024 with a 1-month history of cough.

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

19 Aug 2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Concurrent administration of sacituzumab govitecan and radiotherapy is well tolerated and does not lead to increased toxicity in patients with metastatic breast cancer, a study has shown.

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

14 Aug 2025

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025 by

The E-STOP trial presented at ESHRE 2025 supports early antibiotic suspension in paediatric patients with cancer and febrile neutropenia (FN).

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

14 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Does adjuvant aspirin have a protective effect in resected PIK3CA-mutant colon cancer?

Does adjuvant aspirin have a protective effect in resected PIK3CA-mutant colon cancer?

Treatment further worsens physical function in NSCLC

Treatment further worsens physical function in NSCLC

Dalpiciclib-pyrotinib-endocrine therapy passes trial for breast cancer

Dalpiciclib-pyrotinib-endocrine therapy passes trial for breast cancer

Cancer history does not factor in COVID-19, related outcomes among older women

Cancer history does not factor in COVID-19, related outcomes among older women

Lung nodule surveillance programme helps detect early-stage lung cancer

Lung nodule surveillance programme helps detect early-stage lung cancer

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-July-2025

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Radiotherapy plus sacituzumab govitecan feasible in metastatic breast cancer

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia

Study supports early antibiotic suspension in kids with cancer, febrile neutropenia